ALIVE Israel HealthTech Fund has completed the initial closing of its new vehicle, ALIVE Growth Fund III, and formally launched its investment operations. The dedicated HealthTech and digital health growth fund is targeting total commitments of between $180 million and $200 million, underscoring continued investor appetite for the sector despite volatile markets. The move reinforces ALIVE’s ambition to play a leading role in scaling advanced-stage health technology companies from Israel and around the world.
Fund Strategy and Investment Focus
ALIVE Growth Fund III is structured as a mid to late stage growth fund focused on companies at clear clinical and commercial inflection points. It will back HealthTech and digital health businesses that have already demonstrated substantive traction and are positioned to accelerate revenue growth, expand globally, or reach pivotal regulatory and adoption milestones. The fund intends to deploy capital into both Israeli and international companies that can translate validated innovation into scaled healthcare impact.
Strategic Partnerships and Investor Base
The fund is managed by founding partners Prof. Rafi Beyar, Prof. Ari Shamiss, Michel Habib, and Dudi Klein, who bring a mix of clinical, operational, and investment experience from leading healthcare institutions and venture platforms. ALIVE operates on a partnership model with major healthcare providers, including the Maccabi and Assuta groups in Israel and the Carilion Clinic network in the United States, giving portfolio companies direct access to sophisticated clinical environments and large patient populations. Alongside these strategic partners, anchor financial investors such as Leumi Partners and Menora have renewed their commitments from earlier ALIVE vehicles, signaling confidence in both the team and its strategy.
Track Record and Market Context
The launch of ALIVE Growth Fund III builds on the performance of ALIVE Fund I and ALIVE Next Fund II, which together have already delivered three exits in the past five years. These include the sale of Innovalve to Edwards and the acquisition of cybersecurity and IoT-focused Cynerio by Axonius, illustrating ALIVE’s ability to identify clinically meaningful technologies and shepherd them to strategic outcomes. That track record, achieved in a period marked by macroeconomic uncertainty and sector-specific headwinds, underpins investor confidence in the firm’s ability to navigate complex markets.
Positioning in the Global HealthTech Landscape
HealthTech and digital health markets are experiencing renewed scrutiny on business fundamentals, which has elevated the importance of specialized funds with deep domain knowledge and curated clinical networks. By concentrating on companies at advanced growth stages, ALIVE aims to bridge the gap between early innovation funding and large-scale commercialization, where many health technology ventures struggle. The combination of hospital partnerships, experienced medical leadership, and committed financial backers is designed to help portfolio companies validate real-world outcomes, meet regulatory requirements, and scale into global markets more efficiently.
ALIVE Growth Fund III’s initial closing represents more than a capital raise, it is a signal of resilience and optimism around Israeli and global HealthTech at a time of ongoing geopolitical and market challenges. With a target fund size of around $200 million, a clear focus on mid to late stage opportunities, and a network of strategic healthcare partners, ALIVE is positioning itself as a key growth catalyst for digital and medical technology innovators. As the fund begins deploying capital, its ability to convert clinical insight and sector expertise into scalable commercial success will determine its contribution to the next generation of global health solutions.